• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
CDX
Click for more information
6.67% 14.0¢

CARDIEX LIMITED - Announcements

Market Cap $17.65M  ! watchlist Created with Sketch. Add to my watchlist

CardieX Limited is an Australia-based digital health technology company. The Company... CardieX Limited is an Australia-based digital health technology company. The Company develops and markets noninvasive patient monitoring technologies for assessing cardiovascular health. It specializes in the development of biomarkers and digital solutions for large-scale cardiovascular health disorders. Its solutions are designed to be deployed at point-of-care for arterial health screening, and as part of a remote patient monitoring regimen to extend care and enhance cardiovascular health outcomes. Its suite of products includes medical and home health devices and digital solutions for hypertension, cardiovascular disease, and other vascular health disorders all based on the Company’s SphygmoCor vascular biomarker technology. Its products include CONNEQT Pulse, SphygmoCor XCEL, and Oscar 2 Ambulatory Blood Pressure Monitor. CONNEQT Pulse measures both brachial and central blood pressures alongside a suite of vascular biomarkers to provide unparalleled insights into vascular health.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
CDX Results of Meeting09/08/12
CDX Chairman's Address to ShareholdersPRICE SENSITIVE08/08/12
CDX Form 603 & Form 60403/08/12
CDX Appendix 4C - quarterlyPRICE SENSITIVE31/07/12
CDX FDA submission for next generation product23/07/12
CDX Notice of General Meeting/Proxy Form06/07/12
CDX Business UpdatePRICE SENSITIVE04/07/12
CDX Becoming a substantial holder28/06/12
CDX +Change in substantial holding from ALF25/06/12
CDX Share trading policy - Update15/06/12
CDX Success share placementPRICE SENSITIVE15/06/12
CDX Reinstatement to Official QuotationPRICE SENSITIVE15/06/12
CDX Cleansing notice15/06/12
CDX Appendix 3B15/06/12
CDX Suspension from Official QuotationPRICE SENSITIVE14/06/12
CDX Trading HaltPRICE SENSITIVE12/06/12
CDX AtCor to enter new market segmentPRICE SENSITIVE07/06/12
CDX Acquisition of Alliance Partner SunTech by Halma plcPRICE SENSITIVE05/06/12
CDX Investor Presentation15/05/12
CDX Ground breaking new product launched and European Congress01/05/12
CDX Appendix 4C - quarterlyPRICE SENSITIVE24/04/12
CDX New CPT code to be establishedPRICE SENSITIVE07/03/12
CDX Half Yearly Report and AccountsPRICE SENSITIVE16/02/12
CDX AtCor awarded $1.1 million Commercialisation Australia grantPRICE SENSITIVE02/02/12
CDX First half market updatePRICE SENSITIVE31/01/12
CDX Appendix 4C - quarterlyPRICE SENSITIVE31/01/12
CDX Strategic Alliance with SunTech MedicalPRICE SENSITIVE23/01/12
CDX Ceasing to be a substantial holder12/01/12
CDX Three US medical associations support central BP assessmentPRICE SENSITIVE11/01/12
CDX +Change in substantial holding from ALF06/12/11
CDX US$0.9 million pharmaceutical contractPRICE SENSITIVE02/11/11
CDX Appendix 3B28/10/11
CDX Change of Director's Interest Notice27/10/11
CDX Results of Meeting21/10/11
CDX Appendix 4C - quarterlyPRICE SENSITIVE21/10/11
CDX Chairmans Address21/10/11
CDX Presentation to Shareholders21/10/11
CDX Positive Medicare ruling in New York StatePRICE SENSITIVE13/10/11
CDX US$1.86 million new pharmaceutical contractsPRICE SENSITIVE10/10/11
CDX Annual Report to shareholders20/09/11
CDX Proxy voting form20/09/11
CDX Notice of Annual General Meeting20/09/11
CDX Change in substantial holding02/09/11
CDX +Change in substantial holding from ALF29/08/11
CDX FY2012 revenue updatePRICE SENSITIVE29/08/11
CDX Preliminary Final ReportPRICE SENSITIVE26/08/11
CDX Market UpdatePRICE SENSITIVE28/07/11
CDX Appendix 4C - quarterlyPRICE SENSITIVE28/07/11
CDX Worldwide agreement with SunTech MedicalPRICE SENSITIVE27/07/11
CDX Ceasing to be a substantial holder18/07/11
CDX Change in substantial holding07/07/11
CDX US$1.25 million new pharmaceutical contractsPRICE SENSITIVE01/07/11
CDX Change in substantial holding27/06/11
CDX +Change in substantial holding from ALF24/06/11
CDX Change of Directors Interest Notice - Revision18/05/11
CDX Outstanding options17/05/11
CDX Change of Director's Interest Notice17/05/11
CDX Lowering central blood pressure shown to reverse heart damag17/05/11
CDX Investor presentation06/05/11
CDX +Becoming a substantial holder from ALF05/05/11
CDX Becoming a substantial holder05/05/11
CDX Appendix 4C - quarterlyPRICE SENSITIVE28/04/11
CDX Shareholder update12/04/11
CDX +Sonic Healthcare's Lifescreen to offer SphygmoCor testPRICE SENSITIVE05/04/11
CDX Breaking Study New Alternative in Aortic Pressure MonitoringPRICE SENSITIVE28/03/11
CDX US$0.6 million new pharmaceutical contractPRICE SENSITIVE08/03/11
CDX Change in substantial holding08/03/11
CDX 15-year Taiwanese study endorses central BP measurementPRICE SENSITIVE04/03/11
CDX Change in substantial holding - Amended23/02/11
CDX Change in substantial holding23/02/11
CDX Half Yearly Report and AccountsPRICE SENSITIVE17/02/11
CDX Becoming a substantial holder04/02/11
CDX Appendix 4C - quarterly (revised)31/01/11
CDX First half market update31/01/11
CDX Appendix 4C - quarterlyPRICE SENSITIVE31/01/11
CDX Amended change of directors interest notice24/12/10
CDX Share trading policy23/12/10
CDX US$1.28 million new pharmaceutical contractPRICE SENSITIVE21/12/10
CDX US$250,000 new research salePRICE SENSITIVE20/12/10
CDX Change of Director's Interest Notice x 316/12/10
CDX Top 20 securityholders08/12/10
CDX Appendix 3B08/12/10
CDX Change of Director's Interest Notice x 507/12/10
CDX US$1.1 million new pharmaceutical contractPRICE SENSITIVE06/12/10
CDX Appendix 3B02/12/10
CDX Top 20 securityholders02/12/10
CDX Rights Issue Successfully Completed02/12/10
CDX Results of Meeting24/11/10
CDX AGM presentation23/11/10
CDX Notice of Despatch of Rights Issue Documents08/11/10
CDX US Therapeutic Project GrantPRICE SENSITIVE04/11/10
CDX Appendix 4C - First Quarter ReportPRICE SENSITIVE27/10/10
CDX Appendix 3B - Placement26/10/10
CDX Rights Offer BookletPRICE SENSITIVE22/10/10
CDX Cleansing Notice22/10/10
CDX Notice of AGM21/10/10
CDX Letter to optionholders - rights issue21/10/10
CDX Appendix 3B - Rights Issue21/10/10
CDX Letter to shareholders - rights issue21/10/10
CDX Rights issue - amended timetable21/10/10
CDX Results of Meeting
09/08/12
CDX Chairman's Address to Shareholders
08/08/12PRICE SENSITIVE
CDX Form 603 & Form 604
03/08/12
CDX Appendix 4C - quarterly
31/07/12PRICE SENSITIVE
CDX FDA submission for next generation product
23/07/12
CDX Notice of General Meeting/Proxy Form
06/07/12
CDX Business Update
04/07/12PRICE SENSITIVE
CDX Becoming a substantial holder
28/06/12
CDX +Change in substantial holding from ALF
25/06/12
CDX Share trading policy - Update
15/06/12
CDX Success share placement
15/06/12PRICE SENSITIVE
CDX Reinstatement to Official Quotation
15/06/12PRICE SENSITIVE
CDX Cleansing notice
15/06/12
CDX Appendix 3B
15/06/12
CDX Suspension from Official Quotation
14/06/12PRICE SENSITIVE
CDX Trading Halt
12/06/12PRICE SENSITIVE
CDX AtCor to enter new market segment
07/06/12PRICE SENSITIVE
CDX Acquisition of Alliance Partner SunTech by Halma plc
05/06/12PRICE SENSITIVE
CDX Investor Presentation
15/05/12
CDX Ground breaking new product launched and European Congress
01/05/12
CDX Appendix 4C - quarterly
24/04/12PRICE SENSITIVE
CDX New CPT code to be established
07/03/12PRICE SENSITIVE
CDX Half Yearly Report and Accounts
16/02/12PRICE SENSITIVE
CDX AtCor awarded $1.1 million Commercialisation Australia grant
02/02/12PRICE SENSITIVE
CDX First half market update
31/01/12PRICE SENSITIVE
CDX Appendix 4C - quarterly
31/01/12PRICE SENSITIVE
CDX Strategic Alliance with SunTech Medical
23/01/12PRICE SENSITIVE
CDX Ceasing to be a substantial holder
12/01/12
CDX Three US medical associations support central BP assessment
11/01/12PRICE SENSITIVE
CDX +Change in substantial holding from ALF
06/12/11
CDX US$0.9 million pharmaceutical contract
02/11/11PRICE SENSITIVE
CDX Appendix 3B
28/10/11
CDX Change of Director's Interest Notice
27/10/11
CDX Results of Meeting
21/10/11
CDX Appendix 4C - quarterly
21/10/11PRICE SENSITIVE
CDX Chairmans Address
21/10/11
CDX Presentation to Shareholders
21/10/11
CDX Positive Medicare ruling in New York State
13/10/11PRICE SENSITIVE
CDX US$1.86 million new pharmaceutical contracts
10/10/11PRICE SENSITIVE
CDX Annual Report to shareholders
20/09/11
CDX Proxy voting form
20/09/11
CDX Notice of Annual General Meeting
20/09/11
CDX Change in substantial holding
02/09/11
CDX +Change in substantial holding from ALF
29/08/11
CDX FY2012 revenue update
29/08/11PRICE SENSITIVE
CDX Preliminary Final Report
26/08/11PRICE SENSITIVE
CDX Market Update
28/07/11PRICE SENSITIVE
CDX Appendix 4C - quarterly
28/07/11PRICE SENSITIVE
CDX Worldwide agreement with SunTech Medical
27/07/11PRICE SENSITIVE
CDX Ceasing to be a substantial holder
18/07/11
CDX Change in substantial holding
07/07/11
CDX US$1.25 million new pharmaceutical contracts
01/07/11PRICE SENSITIVE
CDX Change in substantial holding
27/06/11
CDX +Change in substantial holding from ALF
24/06/11
CDX Change of Directors Interest Notice - Revision
18/05/11
CDX Outstanding options
17/05/11
CDX Change of Director's Interest Notice
17/05/11
CDX Lowering central blood pressure shown to reverse heart damag
17/05/11
CDX Investor presentation
06/05/11
CDX +Becoming a substantial holder from ALF
05/05/11
CDX Becoming a substantial holder
05/05/11
CDX Appendix 4C - quarterly
28/04/11PRICE SENSITIVE
CDX Shareholder update
12/04/11
CDX +Sonic Healthcare's Lifescreen to offer SphygmoCor test
05/04/11PRICE SENSITIVE
CDX Breaking Study New Alternative in Aortic Pressure Monitoring
28/03/11PRICE SENSITIVE
CDX US$0.6 million new pharmaceutical contract
08/03/11PRICE SENSITIVE
CDX Change in substantial holding
08/03/11
CDX 15-year Taiwanese study endorses central BP measurement
04/03/11PRICE SENSITIVE
CDX Change in substantial holding - Amended
23/02/11
CDX Change in substantial holding
23/02/11
CDX Half Yearly Report and Accounts
17/02/11PRICE SENSITIVE
CDX Becoming a substantial holder
04/02/11
CDX Appendix 4C - quarterly (revised)
31/01/11
CDX First half market update
31/01/11
CDX Appendix 4C - quarterly
31/01/11PRICE SENSITIVE
CDX Amended change of directors interest notice
24/12/10
CDX Share trading policy
23/12/10
CDX US$1.28 million new pharmaceutical contract
21/12/10PRICE SENSITIVE
CDX US$250,000 new research sale
20/12/10PRICE SENSITIVE
CDX Change of Director's Interest Notice x 3
16/12/10
CDX Top 20 securityholders
08/12/10
CDX Appendix 3B
08/12/10
CDX Change of Director's Interest Notice x 5
07/12/10
CDX US$1.1 million new pharmaceutical contract
06/12/10PRICE SENSITIVE
CDX Appendix 3B
02/12/10
CDX Top 20 securityholders
02/12/10
CDX Rights Issue Successfully Completed
02/12/10
CDX Results of Meeting
24/11/10
CDX AGM presentation
23/11/10
CDX Notice of Despatch of Rights Issue Documents
08/11/10
CDX US Therapeutic Project Grant
04/11/10PRICE SENSITIVE
CDX Appendix 4C - First Quarter Report
27/10/10PRICE SENSITIVE
CDX Appendix 3B - Placement
26/10/10
CDX Rights Offer Booklet
22/10/10PRICE SENSITIVE
CDX Cleansing Notice
22/10/10
CDX Notice of AGM
21/10/10
CDX Letter to optionholders - rights issue
21/10/10
CDX Appendix 3B - Rights Issue
21/10/10
CDX Letter to shareholders - rights issue
21/10/10
CDX Rights issue - amended timetable
21/10/10
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
14.0¢ 		Change
-0.010(6.67%) 		Mkt cap ! $17.65M
Open High Low Value Volume
15.5¢ 17.5¢ 13.5¢ $186.0K 1.196M

Buyers (Bids)

No. Vol. Price($)
4 66974 13.5¢
 

Sellers (Offers)

Price($) Vol. No.
14.0¢ 14000 1
View Market Depth
Last trade - 13.57pm 15/11/2024 (20 minute delay) ?
Last
14.0¢ 		  Change
-0.010 ( 3.45 %)
Open High Low Volume
15.0¢ 17.0¢ 13.5¢ 497524
Last updated 14.31pm 15/11/2024 ?
CDX (ASX) Chart

Top Stories

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

InhaleRX Ltd has received approval for a Phase 2 clinical trial to test its novel therapy IRX-211 for treatment of Breakthrough Cancer Pain
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks Copper prices slump; Trump Wall Street rally fades; US health stocks dip on RFK appointment – and much more.
Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
Banshee's historic trenches prove rich in antimony and gold for GDM Great Divide Mining Ltd has found high-grade antimony and gold through geochemical sampling at its Banshee prospect in Queensland
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.